Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03726749 · ClinicalTrials.gov registry record · Phase 4
Tocilizumab Plus a Short Prednisone Taper for GCA
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT03726749: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT03726749 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03726749, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.
Interventions
- DRUG Prednisone
- DRUG Tocilizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2018-11-28 |
| Est. Completion | 2021-12-29 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03726749
The ClinicalTrials.gov registry entry for NCT03726749 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT03726749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03726749 about?
NCT03726749 is a clinical study titled "Tocilizumab Plus a Short Prednisone Taper for GCA". This is an open-label pilot study of tocilizumab (TCZ) 162 mg weekly administered subcutaneously for 52 weeks in combination with 8 weeks of oral prednisone.
What is the current status of trial NCT03726749?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2018-11-28. Estimated completion is 2021-12-29.
What interventions are being tested in trial NCT03726749?
The interventions under investigation include: Prednisone (DRUG), Tocilizumab (DRUG).
Who is sponsoring clinical trial NCT03726749?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.